Ashland innovative supplier partnership powers sustainable, profitable growth for local farmers and small villages in India

Written by Customer Service on April 3, 2022. Posted in Public Companies.

Responsible Solvers™ initiative increases farmers’ yield and income, lowers production costs, expands local economy, and positively impacts the environment PHC22-012_inCos_MR1_BOX-11_1125x1125x150 Ashland Responsible Solvers™ initiative in Rajasthan, India increases farmers’ yield and income, lowers production costs, expands local economy, and positively impacts the environment PHC22-012_inCos_MR1_BOX-11_1125x1125x150-V2 Responsibly solving for a better world, Ashland announces innovative supplier partnership that powers sustainable, profitable growth for local farmers and small villages in India PHC22-012_inCos_MR1_BOX-2_750x375x100 Ashland teamed up with the SM Sehgal Foundation to increase the volume of guar harvested annually through educational programs and scientific solutions for sustainable farming, while respecting the sourcing...

HII Launches National Security Cutter Calhoun (WMSL 759)

Written by Customer Service on April 3, 2022. Posted in Public Companies.

PASCAGOULA, Miss., April 03, 2022 (GLOBE NEWSWIRE) — HII (NYSE: HII) launched the Legend-class national security cutter Calhoun (WMSL 759) on Saturday at the company’s Ingalls Shipbuilding division. Launching Calhoun is the first of a series of significant milestone events in bringing the ship to life. “The national security cutters are critically important to the safety and security of our country,” said Kari Wilkinson, president of HII’s Ingalls Shipbuilding division. “I am very proud of our NSC team who continues to build efficiencies into a mature program line to deliver the Coast Guard’s most advanced cutters. Our shipbuilders are proud and honored to build these magnificent ships, and we know that this ship named after the first Master Chief Petty of the Coast Guard, Charles L. Calhoun, has special meaning for the U.S. Coast...

JSC “Latvijas Gāze” announcement on the supply of natural gas

Written by Customer Service on April 3, 2022. Posted in Public Companies.

JSC “Latvijas Gāze” has entered into a valid long-term agreement on the supply of natural gas until 2030 with PJSC “Gazprom”, which provides for settlements for natural gas in euros. According to the changes in the legislation of the Russian Federation, starting from April 1, 2022, settlements for natural gas supplies made after April 1, 2022 in accordance with the foreign trade agreements of PJSC “Gazprom” for the supply of natural gas abroad (to a number of countries) shall be made only in Russian rubles. Assessing the compliance of the said change of the settlement procedure with the previously established sanction regime, the first impression is that such settlement procedure – in Russian rubles – does not formally violate the sanction regime and is possible. At present, Latvijas Gāze continues to analyze in depth the change...

Zio® by iRhythm Shown to Prevent Hospital Admissions, Aid in Early Detection of AF

Written by Customer Service on April 3, 2022. Posted in Public Companies.

New clinical research presented at ACC.22 shows that the Zio service is a viable solution for the early detection of silent atrial fibrillation Additional data shows that Zio AT can positively impact hospital resources – saving one healthcare system 136 inpatient hospitalization days SAN FRANCISCO, April 03, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, announces the results of three clinical research studies presented at The American College of Cardiology’s 71st Annual Scientific Session & Expo (ACC.22). The new clinical evidence: Further validates the Zio service as a viable solution for the early detection of atrial fibrillation (AF),1 helping undiagnosed populations effectively seek treatment before more serious...

<div>Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo</div>

Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo

Written by Customer Service on April 3, 2022. Posted in Public Companies.

New Analyses of thousands of patients spanning Phase 2 and pooled Phase 3 data demonstrate that NEXLETOL safely and significantly lowers LDL-C compared to placebo in patients with renal impairment or hypertension ANN ARBOR, Mich., April 03, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL®) at the American College of Cardiology’s 71st Annual Scientific Session & Expo (ACC.22). The first analysis titled, “Safety and Efficacy of Bempedoic Acid in Patients with Renal Impairment,” was presented by Peter P. Toth, MD, PhD, FCCP, FAHA, FESC, FACC. This analysis of a total of 3,619 patients included in four Phase 3 studies demonstrated that bempedoic acid 180 mg significantly lowered low-density lipoprotein cholesterol (LDL-C) (p

Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session

Written by Customer Service on April 3, 2022. Posted in Public Companies.

No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction in METEORIC-HF Healthcare Resource Utilization and Cost Analysis from GALACTIC-HF Demonstrate Treatment with Omecamtiv Mecarbil Led to 19% Cost Reduction Per Patient in Key Subgroup Additional Results from GALACTIC-HF Indicate Treatment with Omecamtiv Mecarbil Associated with Similar Risk Reduction in Both Hospitalized Patients and Outpatients SOUTH SAN FRANCISCO, Calif., April 03, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the full results from METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), a Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure with reduced ejection...

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Written by Customer Service on April 3, 2022. Posted in Public Companies.

– NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout the study. At Month 30, median change from baseline in NT-proBNP was -437 pg/mL with 68% of participants observing NT-proBNP levels below their baseline – Serum TTR levels were sustainably increased from baseline, with mean concentration rising from 21.55 mg/dL at baseline to 30.06 mg/dL at Month 30 (+41%) – Acoramidis remained generally well-tolerated with no safety signals of clinical concern identified – Topline data from ongoing Phase 3 trial of acoramidis in ATTR-CM (ATTRibute-CM) are expected in mid-2023 PALO ALTO, Calif., April 03, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical...

Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for Anti-CD112R Monoclonal Antibody for Treatment of Advanced Solid Tumors

Written by Customer Service on April 3, 2022. Posted in Public Companies.

SHANGHAI, China, April 03, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its anti-CD112R monoclonal antibody (TAB009/JS009) for the treatment of advanced solid tumors. TAB009/JS009 is a recombinant humanized IgG4 monoclonal antibody against human CD112R developed independently by Junshi Biosciences, for the treatment of advanced malignant tumors. CD112R, also known as PVRIG (Poliovirus receptor-related immunoglobulin domain-containing protein), is a new immune checkpoint pathway discovered by the company....

InterCure to Announce Q4 & Year-End 2021 Financial Results on April 4, 2022

Written by Customer Service on April 3, 2022. Posted in Public Companies.

Will release financial results for the fourth quarter of 2021 before market open on Monday, April 4, 2022 Webcast scheduled for same day at 8:30am ET NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2022 (GLOBE NEWSWIRE) — InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“InterCure” or the “Company”) today announced that the Company will release financial results for its fourth quarter fiscal 2021 ended December 31, 2021 before financial markets open on April 4, 2022. InterCure executives will host a live conference call and audio webcast to discuss these results at 8:30 am Eastern Time, details of which are provided below. To access the conference call, United States participants please dial (844) 310-5056, or for international callers, 1-706-679-4749. Conference ID: 5661207. Participants can...

Day: April 3, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice